About

What we do

About

Our Mission

Phaeno, Inc. has been created to advance original concepts and technology in pursuit of precision medicine.

Phaeno will transform biomedical approaches to a wide range of diseases from Alzheimer’s, Parkinson’s and advanced cancers; to AIDS, Lyme and Covid-19. Our proprietary Precision Sequencing technology has solved a longstanding technical limitation with accurate large scale, full length, single molecule sequencing. This technology can pinpoint the molecules responsible for disease and the drug targets for treatment.

WHO WE ARE

Founders

William S. Agnew

William S. Agnew, Ph.D, CEO — Professor of Physiology and Neuroscience, former Chairman of Physiology, Johns Hopkins University School of Medicine. Molecular Neurobiologist, Co-inventor.

Mark Emerick

Mark C. Emerick, Ph.D — Adjunct Research Scientist, Department of Physiology, Emory University School of Medicine. Molecular Neurobiologist, Co-inventor.

Giovanni Parmigiani

Giovanni L. Parmigiani, Ph.D — Professor Department of Data Science, Dana Farber Cancer Institute and Associate Director for Population Sciences, Dana Farber / Harvard Cancer Center

Hedi Mouchard

Hedi Mouchard, Chief Operating Officer, Phaeno Inc.